Advancis looks to cut costs following trial failure

Days after its lead product failed a second Phase III trial, the CEO of Advancis told analysts that he was looking at cutting costs, including possible layoffs. Advancis had been developing a new form of the antibiotic amoxicillin, but it has now failed pivotal trials for adults and children. The biotech has about $40 million in cash on hand.

- read this report from Washington Business Journal for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.